DOCSLIB.ORG

Lok Sabha Secretariat (LARRDIS) New Delhi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lok Sabha Secretariat (LARRDIS) New Delhi Lok Sabha Secretariat (LARRDIS) New Delhi BACKGROUND NOTE on “Status of COVID - 19 Vaccine production in India” (For the use of the Standing Committee on Chemicals and Fertilisers) October 2020 ____________________________________________________________________________ The brief note is intended to serve only as a background aid to the Standing Committee on Chemical and Fertilisers. It is for restricted circulation and not for publication in any form. [Prepared by the Educational & Scientific Affairs Wing of the R&I Division. Officers associated with the preparation - Babulal Naik, Additional Director;Ms. Namita Kumari, RO; supervised by Shri Pradosh Panda, Director. Feedback is welcome and may be sent to [email protected]] Status of COVID - 19 vaccine production in India LARRDIS October 2020 Introduction India has the world's second largest coronavirus cases after the United States. However, after 8 months since the pandemic hit the country, the rising per day COVID cases curve has started to decline, especially at a time when a possible launch of coronavirus vaccine is being hoped by many by early 2021. COVID-19 is a new strain of coronavirus that has not been previously identified in humans. The COVID-19 is the cause of an outbreak of respiratory illness first detected in Wuhan, Hubei province, China. Since December 2019, cases have been identified in a growing number of countries. The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 118,567 lives till 25th October 2020 in the country1. Source : Ministry of Health and Family Welfare dated 27 th Oct 2020 The whole world is waiting eagerly for an effective vaccine to fight the coronavirus pandemic. It has not only claimed lives, but also impacted people, both physically and mentally. Globally, India is renowned to be a leading vaccine producer and has manufactured several vaccines in the past, which experts believe gives India an edge over its competitors.There are more than 170 vaccines in progress right now, but closer home we have our hopes pinned on India’s first vaccine called Covaxin.2Covaxin is the first indigenous vaccine developed by India against COVID-19 and is derived from a 1 https://www.worldometers.info/coronavirus/country/india/ 2 https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/indias-first-coronavirus-vaccine-here-is- everything-we-know-about-its-development/articleshow/78613573.cms Page 2 Status of COVID - 19 vaccine production in India LARRDIS October 2020 strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. A number of companies and independent medical groups are involved in the development of a COVID-19 vaccine.Many more developments and announcements are taking place in the production of a homegrown vaccine. PM CARES Fund has extended support to the tune of ₹ 100 crore for coronavirus vaccine development efforts. According to the World Health Organization’s latest count, 13 experimental vaccines are being tested in humans and more than 120 others are in earlier stages of development even as the infections near nine million, including 468,484 deaths. Even as the Covid-19 pandemic has set off an unprecedented response among the global scientific community to find a vaccine, the race is set to kick up a notch from next month as three candidates — the ones developed by Moderna Inc, China’s Sinovac Biotech and UK’s Oxford- 3 AstraZeneca — are set to enter late-stage trials. Source: https://www.worldometers.info/coronavirus/country/india/ 3 https://indianexpress.com/article/explained/how-close-are-we-to-coronavirus-covid-19-vaccine-what-is-the- testing-process-6471283/ Page 3 Status of COVID - 19 vaccine production in India LARRDIS October 2020 Source: https://www.worldometers.info/coronavirus/country/india/ The Department of Biotechnology has been made a central coordination agency to identify pathways for vaccine development.4 Recently, Our Prime Minister in an address to the 2020 summit of the Grand Challenge on COVID-19 Vaccine development stated that India has one of the highest recovery rates of COVID-19 infections at 88 percent and the country is at the "forefront" of vaccine development. This meeting brought together policymakers and scientific leaders for a deepened scientific collaborations in solving global health problems, with great emphasis on COVID-19 with an "India for the World" framing.5 What is COVID -19 In February 2020, the World Health Organization coined the official name for the disease-causing the 2019 novel coronavirus outbreak. The new virus and disease were unknown before the outbreak began in Wuhan, China, in December 4 https://www.ndtv.com/india-news/coronavirus-pandemic-covid-19-vaccine-development-at-early-stage-in-india- breakthrough-unlikely-within-a-year-experts-2234047 5 Oct 20, 2020 07:33 AM IST | Source: Moneycontrol.com Page 4 Status of COVID - 19 vaccine production in India LARRDIS October 2020 2019.The new name of this disease is coronavirus disease 2019, abbreviated as COVID-19. In COVID-19, ‘CO’ stands for ‘corona,’ ‘VI’ for ‘virus,’ and ‘D’ for disease.6 Coronaviruses (CoV) are a large family of viruses that can cause illness ranging from the common cold to a more severe disease such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are zoonotic, meaning they are transmitted between animals and people. In March 2020, the WHO declared the COVID-19 outbreak a pandemic. Detailed investigations found that SARS-CoV was transmitted from civet cats to humans and MERS-CoV from dromedary camels to humans. Several known coronaviruses are circulating in animals that have not yet infected humans. Novel (meaning new) coronavirus (nCoV) is a new strain that had not been previously identified in humans. On 31 December 2019, WHO was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China. A novel coronavirus (2019-nCoV) was identified as the causative virus by Chinese authorities on 7 January, 2020. Available evidence on the 2019-nCoV virus and previous experience with other 6 https://know.rx.health/support/solutions/articles/48001160489-what-is-covid-19- Page 5 Status of COVID - 19 vaccine production in India LARRDIS October 2020 coronaviruses (MERS-CoV and SARS-CoV) and other respiratory viruses (e.g avian influenza) suggest that there may be zoonotic transmission associated with the 2019-nCoV. The virus that causes COVID-19 and the one that caused the outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003 are related to each other genetically, but the diseases they cause are quite different. SARS was more deadly but much less infectious than COVID-19. There have been no outbreaks of SARS anywhere in the world since 2003.7 The different phases of vaccine testing Pre-clinical tests: In this stage, scientists test the vaccine in the laboratory using cells or animals. Phase I trials: This is the first step where the experimental vaccine is given to humans and examines the safety, dosage, and possible side effects. This stage typically takes around two months and involves small numbers of participants, usually 20 to 100 healthy volunteers. Phase II trials: In this stage, several hundred individuals are enrolled for testing and they are split into groups age-wise such as children and elderly. This stage studies the candidate vaccine’s immunogenicity, proposed doses, schedule of immunisations and method of delivery. Phase III trials: In this stage, the candidate vaccine is tested in hundreds to thousands of volunteers for its ability to prevent infection in humans in real-life situations (outside of laboratory conditions). During a pandemic, a vaccine may receive emergency use authorisation before a formal green signal. Approval: After Phase III trials, the developer submits a license application to the 7 https://www.mohfw.gov.in/ Page 6 Status of COVID - 19 vaccine production in India LARRDIS October 2020 regulatory authority in their respective country. The regulator then inspects the factory where the vaccine will be made and approves its labelling.8 The Global Progress for Severe Acute Respiratory Syndrome-Coronavirus-2 Vaccines 9 The first coronavirus vaccine trial has been started by the Kaiser Permanente Washington Health Research Institute. This vaccine is known as mRNA-1273 and was developed by the National Institute of Allergy and Infectious Diseases scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.10,11Recently, another adenovirus containing S-protein vaccine came for clinical trial in record time. This vaccine developed by a research group in Jenner Institute at Oxford University in partnership with the UK-based global biopharmaceutical company AstraZeneca. Many academic and industry-based research groups are working on recombinant protein-based approach and mainly focusing on S-protein, viral vector-based vaccines, DNA vaccines, live attenuated vaccines (Serum Institute of India with Codagenix), and inactivated virus vaccines. The major concerns about the current vaccine designs are whether they will be effective due to the high frequency of glycosylation and mutations in the S- 8 https://indianexpress.com/article/coronavirus/covid-19-vaccine-front-runners-oxford-moderna-pfizer-
Load more

Recommended publications
  • In 2020, India Dealt with the First Wave of COVID-19 Pandemic With
    PREFACE n 2020, India dealt with the first wave of COVID-19 pandemic with collective measures, Iscientific approach, and awareness. Undoubtedly the second wave of the pandemic is testing our patience and the extent to which we can all tolerate its fangs. The impact of the second wave has seen shortage of medical oxygen across the nation. But, the intelligent use of technology and well-planned resource allocation to tackle the new wave of the pandemic has been dealt with at a war-footing. The current edition, COVID 2021: Nation’s S&T Efforts Against COVID-19, has been compiled to inform our readers and strengthen the usefulness of any published information. This edition contains compilation and coverage of information related to the capacity enhancement of medical oxygen, start-up spotlights, research contributions, and so on. To bridge the gap among scientific contributions, leadership and administrative efforts, and the perspective of the general public, Vigyan Prasar is continuously reaching out to its audiences in the shape of a regular e-newsletter, taking its mandate of science communication, popularisation and extension to the next level. Our effort is firmly based on the fact that “Science gathers knowledge faster than society gathers wisdom”. The steady increase in the number of recoveries and the significant and continuous decrease in positivity rate provide us the much-needed assurance that this may be the outcome of improving the health infrastructure and making health the cornerstone at the policy level. We wish an engaging reading to our audiences across all strata of the society and look forward to suggestions and feedback at [email protected].
    [Show full text]
  • White Paper on the Management of COVID-19 by the Government of India
    White Paper on the Management of COVID-19 by the Government of India JUNE 2021 TABLE OF CONTENTS 1. Executive Summary…………………………………………... (i) 2. The Need for a White Paper on the Management of the COVID-19 Pandemic………………………………….. 1 3. Early Inaction Against COVID-19………………………….. 5 4. Policy Response to the First Wave………………………… 10 5. Hubris and Political Avarice………………………………… 18 6. Ignoring the Signs and the Science………………………... 27 7. Unforgivable Negligence…………………………..…………. 41 8. Vaccine Mismanagement..……………………………...…… 51 9. Wider Impact of Policy Failures…………………………….. 82 10. The Way Ahead……………………………………………….. 89 11. Annexure 1. Indian National Congress: Compendium of Statements, Letters and Resolutions on COVID-19 (March 2020 - June 2021)…………………………………… A1 Executive Summary The mismanagement of the COVID-19 pandemic has been independent India’s gravest governance failure. The Union government under Prime Minister Narendra Modi did not take adequate measures to prevent and contain the pandemic. Therefore, there is a Need for a White Paper (Chapter-1) that examines the government’s acts of omission and commission, its impact on India and suggests constructive measures to improve policy responses to the current and future waves of the pandemic. The Modi government’s handling of the COVID-19 crisis began with its Early Inaction in January 2020 (detailed in Chapter-2). The government ignored early warnings from experts and political leaders from the Opposition. It failed to learn from the lessons and response models of other countries which had been hit by the pandemic. It did not scale up nationwide the lessons from Kerala’s experience in successfully suppressing a virus outbreak (the Nipah virus).
    [Show full text]
  • FAIRFAX News Release TSX Stock Symbol: FFH and FFH.U
    FAIRFAX News Release TSX Stock Symbol: FFH and FFH.U TORONTO, April 20, 2020 FAIRFAX TO DONATE US$1 MILLION TO ‘PM CARES FUND’ FOR COVID-19 RELIEF IN INDIA Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U), recognizing the unprecedented widespread economic suffering from the COVID-19 pandemic, is donating US$1 million to the Prime Minister’s Citizen Assistance and Relief in Emergency Situations Fund (the “PM CARES Fund”) to aid the Indian Government in providing assistance to its citizens in connection with the COVID-19 pandemic. The donation will be made to the PM CARES Fund on behalf of the Fairfax group of companies, including Fairfax India Holdings Corporation, through Fairfax’s Indian affiliate Fairbridge Capital Private Limited. The PM CARES Fund, chaired by Prime Minister Narendra Modi, was created to provide relief to those affected by the COVID-19 pandemic in India, including the provision of financial assistance to Indian citizens and to support healthcare and other necessary infrastructure. Prem Watsa, Chairman and Chief Executive Officer of Fairfax, commented, “We have been impressed by the Indian government’s rapid and proactive response to the COVID-19 pandemic, including the implementation of one of the strictest lockdowns in the world. Fairfax wishes to assist the Indian Government in its efforts to support many of the most vulnerable members of Indian society, who will be severely impacted by the pandemic.” Fairfax is a holding company which, through its subsidiaries, is engaged in property and casualty insurance and reinsurance and the associated investment management. -30- For further information contact: John Varnell, Vice President, Corporate Development at (416) 367-4941 FAIRFAX FINANCIAL HOLDINGS LIMITED 95 Wellington Street West, Suite 800, Toronto, Ontario, M5J 2N7 Telephone: 416-367-4941 Facsimile: 416-367-4946 .
    [Show full text]
  • Adv. Arvind K. Waghmare
    IN THE HIGH COURT OF JUDICATURE AT BOMBAY, NAGPUR BENCH, NAGPUR PUBLIC INTEREST LITIGATION NO. /2020 PETITIONER : Adv. Arvind K. Waghmare VERSUS RESPONDENTS: PM Cares Fund (Prime Ministers Citizens Assistance and Relief in Emergency Situation), A Public Charitable Trust Created by Union Cabinet of India and others SYNOPSIS Date Events 28.03.20 The respondents-Union Cabinet created a public Charitable Trust name and styled as “PM Cares Fund” (Prime Ministers Citizens Assistance and Relief in Emergency Situations) having the Hon’ble Prime Minister of India as its Chairperson and Ministers from the Department of Defence, Home and Finance were made Ex- Officio Board of Trustees. That the said fund was termed as dedicated National Fund with the prime objective of dealing with any kind of emergency or distress situation posed by the Corona Virus (Covid 19) pandemic and thus aimed at to provide relief to be affected citizen-persons in India. It is thus submitted that the said Fund was created in the extreme health emergency in view of the Covid 19 Pandemic in order to have Assistance from people of the country and also from overseas. It is submitted that at the time of creation of the said Public Charitable Fund “PM Cares Fund”, the certain guidelines with objectives were issued by the respondents- Board of Trustees. It is submitted that as per the said guidelines of the “PM Cares Fund”, it was specifically mentioned therein that apart from the ex-officio chairperson and other 3 ex-officio Trustees, 3 other trustees will be appointed-nominated by the Hon’ble Chairperson of the Trust.
    [Show full text]
  • 'Oxycare' System the Government
    May 13, 2021 – Thursday Key Developments Govt approves procurement of 150,000 units of DRDO's 'Oxycare' system The government on Wednesday approved the procurement of 1,50,000 units of 'Oxycare' system developed by the Defence Research and Development Organisation (DRDO) to help in the treatment of COVID-19 patients.Oxycare is an oxygen supply system based on SpO2 (oxygen saturation) level. The DRDO has already transferred the technology to multiple industries in India for large-scale production of the Oxycare system.The 'Oxycare' systems will be procured for Rs 322.5 crore using the PM-Cares Fund, according to the defence ministry."PM-Cares Fund has accorded sanction for procurement of 1,50,000 units of 'Oxycare' system developed by the DRDO at a cost of Rs 322.5 crore," it said.The ministry said 1,00,000 manual and 50,000 automatic Oxycare systems are being procured. https://www.business-standard.com/article/economy-policy/govt-approves-procurement-of-150-000-units-of- drdo-s-oxycare-system-121051200849_1.html Reserve Bank announces Rs 35,000 crore G-sec Acquisition Programme The RBI on Wednesday announced the second tranche of Open Market Purchase of Government of India Securities under G-sec Acquisition Programme (G-SAP 1.0).As announced in the RBI Governor's statement of May 5, the second tranche of G-sec purchase will involve buying back securities of Rs 35,000 crore.The Reserve Bank will purchase the Government securities maturing between November to March 2035. These securities bear coupon rate ranging from 5.85 per cent to 7.17 per cent.The securities will be bought through a multi-security auction using the multiple price method.The Reserve Bank has reserved the right to decide on the quantum of purchase of individual securities as well as accept bids for less than the aggregate amount.The apex bank will either purchase marginally higher/lower than the aggregate amount due to rounding-off.
    [Show full text]
  • 27, 2021/Sarvana 5, 1943 (Saka) ------Q
    PARLIAMENT OF INDIA RAJYA SABHA ERRATA to the list of Questions for WRITTEN ANSWERS for Tuesday, July 27, 2021/Sarvana 5, 1943 (Saka) ----------------------------------------------------------------------------------------------------------------- Q. No. Corrections ----------------------------------------------------------------------------------------------------------------- 846. May be treated as cancelled. 892. May be treated as cancelled. • In the index, Question No. 846 may be deleted from the Ministry of Finance. • In the index, Question No. 892 may be deleted from the Ministry of Health and Family Welfare. New Delhi, July 26, 2021. Copy to:- 1. Ministry of Finance. 2. Ministry of Health and Family Welfare. 3. Translation Section, Rajya Sabha Sectt. 4. E.O.D., Rajya Sabha Sectt. 5. Table Office (2 spare copies). 6. Questions Branch (25 spare copies). Rajya Sabha List of Questions for WRITTEN ANSWERS to be asked at a sitting of the Rajya Sabha to be held on Tuesday, July 27, 2021/ 05 Sravana, 1943 (Saka) (Ministries : Ayush; Corporate Affairs; Culture; Earth Sciences; Finance; Health and Family Welfare; New and Renewable Energy; Power; Science and Technology; Tourism) Total number of questions -- 160 Status of Medicinal Plants Conservation and Development Areas 801 Shri Sujeet Kumar: Will the Minister of Ayush be pleased to state: (a) the number of Medicinal Plants Conservation and Development Areas (MPCDAs) established under the supervision of the National Medicinal Plants Board, State-wise; (b) the amount of funds sanctioned
    [Show full text]
  • Download (10.57
    1 MSME DI, Cuttack conducts webinar on Oxygen Enrichment Unit developed by CSIR-CMERI CSIR-CMERI 30th April, 2021 In a series of webinars for dissemination of awareness on the Oxygen Enrichment Unit developed by CSIR-CMERI to the MSMEs and other entrepreneurs, MSME DI, Cuttack conducted a webinar on 30.04.2021 amidst the crisis of Oxygen. Prof. (Dr.) Harish Hirani, Director, CSIR-CMERI delivered the key address in the seminar. Mr Pawan Gupta, Director, MSME, Cuttack and Mr S. K. Sahu, Asstt. Director also participated in the above webinar together with participating a number of MSMEs, Entrepreneurs and Startups across the Odisha region. Prof. Harish Hirani, Director, CSIR-CMERI, while interacting with the MSME representatives shared that the MSMEs of the Nation will be playing a decisive factor in tackling the COVID 19 battle. COVID may impair the lungs to a great extent and this impairment can be rectified by Oxygen Therapy. To properly tackle and control the Oxygen crisis, the CSIR-CMERI developed Oxygen Enrichment Unit (OEU) can provide a veritable solution. Besides, even in a Post-COVID scenario, the Oxygen Enrichment Units can be a game-changer for ailing aged persons as well as Therapeutic Usage of Oxygen, because it helps in detoxification. Since the OEU might be the essential equipment of the future, the Cost of the device needs to be optimised and indigenised manufacturing needs to be boosted. The CSIR-CMERI OEU has been developed with a Simple Architecture and Design Philosophy built with easily available Raw Materials. If innovatively used by the MSMEs, a Single Air Compressor strategically placed outside the room can help serve 4-6 patients at one go.
    [Show full text]
  • PRO-ACTIVE MEASURES ADOPTED by GOVT on COVID-19 Panaji
    PRO-ACTIVE MEASURES ADOPTED BY GOVT ON COVID-19 Panaji: May 28, 2021 The Government has adopted various measures to combat the pandemic by creating new infrastructure besides augmenting the existing one apart from making creating awareness among people of the facilities available by using various mediums of communications. Liquid Medical Oxygen On the request of the State Government, the Ministry of Health and Family Welfare, Government of India has allotted 20 MT additional allocation of LMO from LINDE Belloxy, raising the overall supply to 46 MT. Plan to Set up Oxygen Generation Plants ● One PSA Plant is being installed in GMC by GSIDC and is awaiting commissioning. ● PSA oxygen generation plant of 600 LPM capacity is received through the PM Cares Fund for SGDH, Margao. However, the delivery of the compressor is awaited for taking up its installation and commissioning. ● More oxygen generation plants (PSA) have been requested under PM Care Fund for NGDH, Mapusa (1000 LPM), ESI Hospital (1000 LPM), and their delivery is awaited. It is expected by 07/06/2021. Status of Newly built Super Specialty Block at GMC The Super Specialty Block (SSB) at GMC was made partially ready on 08/05/2021 for admissions of COVID patients. 27 patients were admitted on day one, which gradually increased to around 290 patients on 19/05/2021 which included both new admissions and shifting of existing patients from GMC. All efforts are made to see that sufficient beds are made available in the SSB not only to tide over the current situation but for maintaining sufficient numbers of third wave.
    [Show full text]
  • India's Deadly Second Covid-19 Wave: Addressing Impacts & Building
    KEY CONSIDERATIONS: INDIA'S DEADLY SECOND COVID-19 WAVE: ADDRESSING IMPACTS & BUILDING PREPAREDNESS AGAINST FUTURE WAVES INTRODUCTION Since February 2021, countless lives have been lost in India, which has compounded the social and economic devastation caused by the second wave of COVID-19. The sharp surge in cases across the country overwhelmed the health infrastructure, with people left scrambling for hospital beds, critical drugs, and oxygen. As of May 2021, infections began to come down in urban areas. However, the effects of the second wave continued to be felt in rural areas. This is the worst humanitarian and public health crisis the country has witnessed since independence; while the continued spread of COVID-19 variants will have regional and global implications. With a slow vaccine rollout and overwhelmed health infrastructure, there is a critical need to examine India's response and recommend measures to further arrest the current spread of infection and to prevent and prepare against future waves. This brief is a rapid social science review and analysis of the second wave of COVID-19 in India. It draws on emerging reports, literature, and regional social science expertise to examine reasons for the second wave, explain its impact, and highlight the systemic issues that hindered the response. This brief puts forth vital considerations for local and national government, civil society, and humanitarian actors at global and national levels, with implications for future waves of COVID-19 in low- and middle-income countries. This review is part of the Social Science in Humanitarian Action Platform (SSHAP) series on the COVID-19 response in India.
    [Show full text]
  • SUPPLEMENT to SYNOPSIS of DEBATE ______(Proceedings Other Than Questions and Answers) ______Tuesday, July 20, 2021 / Ashadha 29, 1943 (Saka) ______
    RAJYA SABHA _______ SUPPLEMENT TO SYNOPSIS OF DEBATE _______ (Proceedings other than Questions and Answers) _______ Tuesday, July 20, 2021 / Ashadha 29, 1943 (Saka) _______ SHORT DURATION DISCUSSION The management of COVID-19 pandemic, implementation of vaccination policy and challenges of the likely third wave - Contd. SHRI VAIKO: My heart of sorrow goes towards the people, frontline warriors, doctors, nurses and the medical staff who have lost their lives in their endeavour to save the people affected by corona. Since ancient times endemics and pandemics are happening across the world till now. Lakhs and crores of peoples died due to these phenomena. The human civilization has been getting badly affected at intervals. Now, it is Covid-19 or Coronavirus which has come and is killing countless people. There is news that the third wave may come. Even there is a possibility of coming of fourth wave also. The haves and have-nots, the poor people could not afford to get this oxygen and they had to face the end of life. In Chengalpattu and Ooty in Tamil Nadu, vaccine manufacturing companies should be supported by the Central Government. ___________________________________________________ This Synopsis is not an authoritative record of the proceedings of the Rajya Sabha. 33 DR. VINAY P. SAHASRABUDDHE: After almost a century, this country has been engulfed by the Corona tragedy. All the Hon'ble Members expressed their respect and gratitude towards our health workers, doctors, nurses, police and sanitation workers. Hon'ble Prime Minister appealed to the people to express their gratitude towards these very health workers. Every effort of the Prime Minister is opposed.
    [Show full text]
  • Philanthropy and the COVID-19 Response in India by Pritha Venkatachalam, Donald Yeh, and Niloufer Memon May 18, 2020
    Philanthropy and the COVID-19 Response in India By Pritha Venkatachalam, Donald Yeh, and Niloufer Memon May 18, 2020 Table of Contents Introduction ................................................................................................................................................................... 2 Why is philanthropy important in the COVID-19 response in India? ............................................................................ 3 What are potential opportunity areas for philanthropic investment? .......................................................................... 5 Vulnerable populations ............................................................................................................................................. 5 Healthcare continuum............................................................................................................................................... 6 Health system strengthening .................................................................................................................................... 6 Socioeconomic needs ................................................................................................................................................ 7 Learnings from the response so far ............................................................................................................................... 8 How can philanthropic action be most impactful? .......................................................................................................
    [Show full text]
  • Csrtimes.Org INDIA’S NO
    RNI NO. DELENG/2013/49640 AUGUSTJUNE 20192020 | VOLUME 78 | ISSUE 86 | `100 www.csrtimes.org INDIA’S NO. 1 CORPORATE SOCIAL RESPONSIBILITY MAGAZINE CSRCSR FOR FOR PMPM CARESCARES FUND | | FUNDCSR TIMES JUNE 2020 1 Atul Sobti Venkat K. Narayana Director General, SCOPE Founder, KVN Foundation CSR TIMES | JUNE 2020 | 2 FROM THE EDITOR INDIA FIGHTS COVID CHALLENGE IN LETTER AND SPIRIT HARISH CHANDRA e are amidst a pandemic and economic crisis. The severity of it has shaken the human race but has not broken its spirits. CSR Times Wepitomizes that spirit of the human race and has brought out the June ‘Prime Minister’s issue, highlighting the efforts of our leaders, businesses and ordinary citizens of their fight against COVID-19. CITIZEN ASSISTANCE Leading from the front, Prime Minister Narendra Modi, realized that the AND RELIEF IN country would require considerable resources to fight the virus. A visionary, he EMERGENCY realized that a fund is needed that can work to help the poor and needy quickly. The fund has to be free of rules that delay disbursement than hastening its SITUATIONS FUND (PM delivery to the beneficiaries. CARES FUND) WAS ‘Prime Minister’s Citizen Assistance and Relief in Emergency Situations SET UP AS A Fund (PM CARES Fund) was set up as a Charitable Trust. We have made this CHARITABLE TRUST. as our cover story of this issue to highlight the vision and mission behind this fund. As a responsible magazine, we believe, that facts have to be told upfront WE HAVE MADE THIS and analysis later. AS OUR COVER STORY This issue of CSR Times has been brought out for you, overcoming many OF THIS ISSUE TO logistics and editorial challenges.
    [Show full text]